The Department of Justice (DOJ) and the Federal Trade Commission (FTC) are conducting a series of listening sessions aimed at exploring ways to reduce drug prices for Americans through enhanced competition. These sessions are particularly focused on identifying and addressing anticompetitive behaviors exhibited by pharmaceutical companies that hinder the entry of generic and biosimilar drugs into the market.

During these discussions, stakeholders, including healthcare professionals, consumer advocates, and industry representatives, are invited to share their insights and experiences regarding the barriers to competition in the pharmaceutical sector. The DOJ and FTC are particularly interested in understanding how certain practices may delay or prevent the availability of more affordable medication options for consumers.

The sessions are part of a broader initiative to ensure that the pharmaceutical market operates fairly and competitively, ultimately benefiting consumers by lowering drug prices. The agencies are committed to taking action against any anticompetitive conduct that restricts market access for generic and biosimilar products.